Skip to main content

September 2011, Vol 4, No 5

In Search of Stakeholder Collaboration to Stem the Cardiometabolic Epidemic

Dalia Buffery, MA, ABD

Original Research

Obesity in the Workplace: Impact on Cardiovascular Disease, Cost, and Utilization of Care

Alberto M. Colombi, MD, MPH, G. Craig Wood, MS

Stakeholder Perspective

Employers’ Obesity Initiatives in the Workplace: A Wakeup Call for Health Plans

by Wayne M. Lednar, MD, PhD

A Call to Action: Responding to the Future Forecasting of Cardiovascular Disease in America

Robert Lee Page ii, PharmD, MSPH, FAHA, FCCP, FASCcP, FASHP, BCPS, Vahram Ghushchyan, PhD, Kavita Nair, PhD

Stakeholder Perspective

Prevention Efforts before Disease Strikes the Key to a Healthy Population of Young Adults

by James T. Kenney, RPh, MBA

Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications

Henry J. Riordan, PhD, Paola Antonini, MD, PhD, Michael F. Murphy, MD, PhD

Stakeholder Perspective

The Complexities of Treating Mental Illness

by Atheer A. Kaddis, PharmD

Current Therapies and Emerging Drugs in the Pipeline for Type 2 Diabetes

Karmella T. Thomas, BS, RD, Katie B. Lyons, MS II, Loida D. Nguyen, PharmD, BCPS, Raymond A. Plodkowski, MD, Quang T. Nguyen, DO, FACE, FTOS

Stakeholder Perspective

New Therapies with Novel Mechanisms of Action Are Urgently Needed for Type 2 Diabetes

by James V. Felicetta, MD

Lipid Management in Patients with Type 2 Diabetes

Marsha J. Daniel, PharmD, cPh, CDE

Stakeholder Perspective

The Time Is Now to Promote Aggressive Lipid Management to Prevent Macrovascular Complications in Patients with Type 2 Diabetes

by Gary M. Owens, MD

Results 1 - 6 of 6